RxDoctor Payments Data

Dennis Jensen, MD

Family Medicine · Lenexa, KSNPI 1336192442

Payments from drug & device makers

$8,605in general payments, 2019–2025

Across 550 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Pfizer$735
  • Novo Nordisk$722
  • AstraZeneca$518
  • Boehringer Ingelheim$408
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,593100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)69$1,145
Lilly USA, LLC71$1,127
Pfizer50$735
Novo Nordisk51$722
AstraZeneca35$518
Boehringer Ingelheim26$408
Amgen24$390
Amarin Pharma, Inc.24$355
GSK21$312
Takeda Pharmaceuticals U.S.A., Inc.14$201
Teva Pharmaceuticals USA, Inc.11$189
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$185
Johnson & Johnson12$185
Nestle Healthcare Nutrition Inc.12$180
Exact Sciences3$150
Merck11$147
Novartis8$119
Upsher-smith Laboratories LLC6$98
Abbott5$94
Gilead5$79
Sanofi-aventis U.S. LLC4$62
Eisai Inc.3$62
Avanir Pharmaceuticals, Inc.4$62
Biohaven Pharmaceuticals, Inc.4$60
Kowa Pharmaceuticals America, Inc.4$59
Collegium Pharmaceutical, Inc.5$58
Scilex Pharmaceuticals Inc.4$54
Astellas Pharma US Inc4$52
E.r. Squibb & Sons, L.L.C.3$49
Otsuka America Pharmaceutical, Inc.2$40
Boston Scientific2$37
Ardelyx, Inc.2$36
IBSA Pharma Inc.2$33
Sanofi Pasteur Inc.2$29
Genentech USA, Inc.2$29
Ironwood Pharmaceuticals, Inc2$27
Supernus Pharmaceuticals, Inc.2$26
Medtronic2$24
Daiichi Sankyo Inc.1$24
Biohaven Pharmaceutical Holding Company Ltd.1$23
Mylan Pharmaceuticals Inc.1$21
UCB, Inc.1$21
Sunovion Pharmaceuticals Inc.1$19
Neos Therapeutics, LP1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Esperion Therapeutics, Inc.1$19
Phathom Pharmaceuticals, Inc.1$19
Shionogi Inc1$18
Lundbeck LLC1$18
Vanda Pharmaceuticals Inc.1$16
Circassia Inc.1$16
Agile Therapeutics, Inc.1$15
Bayer1$14
Bausch Health US, LLC1$14
Neuronetics, Inc.1$14
Agios Pharmaceuticals, Inc.1$14
Adlon Therapeutics L.p.1$14
Jazz Pharmaceuticals Inc.1$14
Currax Pharmaceuticals LLC1$13
Tolmar, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,605 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$54,218
Medicare patients
220
Services billed
1,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide69$81,327
OzempicSemaglutide62$69,129
JardianceEmpagliflozin55$62,850
EliquisApixaban58$47,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$39,177
ArexvyRsvpref3 Antigen/As01e/Pf60$17,485
VyvanseLisdexamfetamine Dimesylate26$9,698
LinzessLinaclotide16$8,982
GlyxambiEmpagliflozin/Linagliptin11$7,994
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,263
Buprenorphine17$6,526
Atorvastatin Calcium495$5,591
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$5,123
Aripiprazole27$3,719
Gabapentin131$2,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,127$81,32769 claims
Boehringer IngelheimJardiance, Glyxambi$408$70,84466 claims
Novo NordiskOzempic$722$69,12962 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$312$63,924129 claims
PfizerEliquis$735$47,77058 claims
AbbVieLinzess, Synthroid$1,145$11,22339 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$201$9,69826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Lenexa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →